Keywords: permax, competition, slashes, amarin, sales, uk-headquartered, corp
Permax competition slashes Amarin sales
Article | 18 August 2003
UK-headquartered Amarin Corp, which has 11 drugs on the US market, reported second-quarter 2003 revenues of $2.6 million, a plunge of 87% from $20.2 million ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Encouraging results with Sangamo's SB-728-T in HIV treatment
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
- Neovacs moving forward in rheumatoid arthritis, say analysts
